Steven Gannon's most recent trade in Xenon Pharmaceuticals Inc was a trade of 10,507 Share Option (Right to Buy) done . Disclosure was reported to the exchange on June 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 10,507 | 10,507 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 2,645 | 13,286 (0%) | 0% | - | Common Shares | |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 2,645 | 0 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 1,593 | 1,593 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Steven Gannon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.41 per share. | 01 Jun 2026 | 1,416 | 11,870 (0%) | 0% | 53.4 | 75,629 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 3,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 12 May 2026 | 3,500 | 10,641 (0%) | 0% | 7.4 | 25,830 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 17,012 | 17,012 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 2,645 | 2,645 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Steven Gannon | Director | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 05 Jun 2025 | 3 | 7,141 (0%) | 0% | 30.3 | 91 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 5,144 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Steven Gannon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.57 per share. | 14 May 2025 | 5,144 | 7,144 (0%) | 0% | 12.6 | 64,660 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 15,542 | 15,542 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Steven Gannon | Director | Sale of securities on an exchange or to another person at price $ 46.25 per share. | 07 Mar 2024 | 5,000 | 9,000 (0%) | 0% | 46.3 | 231,250 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Sale of securities on an exchange or to another person at price $ 46.30 per share. | 07 Mar 2024 | 5,000 | 4,000 (0%) | 0% | 46.3 | 231,513 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Sale of securities on an exchange or to another person at price $ 46.20 per share. | 07 Mar 2024 | 2,000 | 2,000 (0%) | 0% | 46.2 | 92,402 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Sale of securities on an exchange or to another person at price $ 46.45 per share. | 07 Mar 2024 | 1,000 | 14,000 (0%) | 0% | 46.5 | 46,450 | Common Shares |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 18,475 | 18,475 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Purchase of securities on an exchange or from another person at price $ 2.03 per share. | 11 Aug 2022 | 44,400 | 56,400 | - | 2.0 | 90,132 | Common Stock |
| Xenon Pharma Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Purchase of securities on an exchange or from another person at price $ 7.99 per share. | 23 Aug 2021 | 2,829 | 12,000 | - | 8.0 | 22,590 | Common Stock |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Purchase of securities on an exchange or from another person at price $ 8.05 per share. | 18 Aug 2021 | 3,000 | 9,171 | - | 8.1 | 24,150 | Common Stock |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Purchase of securities on an exchange or from another person at price $ 8.05 per share. | 18 Aug 2021 | 171 | 6,171 | - | 8.1 | 1,377 | Common Stock |
| Fusion Pharmaceuticals Inc | Steven Gannon | Director | Purchase of securities on an exchange or from another person at price $ 8.10 per share. | 16 Aug 2021 | 6,000 | 6,000 | - | 8.1 | 48,600 | Common Stock |